Physician

Ajitpal Grewal, M.D.

According to 2025 Medicare claims, Ajitpal Grewal, M.D. (NPI: 1891105276) practices anesthesiology in the Lebanon, PA market, with the plurality of this provider's patient population coming from Lebanon, PA. This provider's primary affiliated billing organization is WELLSPAN MEDICAL GROUP (NPI: 1518475029; TIN: 23-2730785) and primary practice location at 17042-7482. Grewal is affiliated with the WellSpan Population Health Services (ACO ID: A2500), participating under the MSSP model.

Grewal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 247 traditional Medicare patients, billed 1,381 HCPCS/CPT codes, and received $72,738 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,149 prescription claims across 251 beneficiaries totaling $12,583 in drug costs, led by Gabapentin (Gabapentin). Open Payments data shows 1 records totaling $23. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $2,484 to $12,583. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$36K$73K2020 Medicare payment: $6,266 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $45,153 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $66,972 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $58,052 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $72,738 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
20202765$6,266
2021132541$45,153
2022231785$66,972
2023213686$58,052
20242471,381$72,738

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$11K$22K2015 Drug cost: $2,484 (USD; Tot_Drug_Cst)2019 Drug cost: $1,524 (USD; Tot_Drug_Cst)2020 Drug cost: $4,046 (USD; Tot_Drug_Cst)2021 Drug cost: $12,805 (USD; Tot_Drug_Cst)2022 Drug cost: $20,773 (USD; Tot_Drug_Cst)2023 Drug cost: $22,013 (USD; Tot_Drug_Cst)2024 Drug cost: $12,583 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20152263$2,484
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
20192945$1,524
202069142$4,046
2021128408$12,805
2022188750$20,773
20232291,007$22,013
20242511,149$12,583

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99204New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more141141$108
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more149304$88
62323Injection of substance into lower spine canal using imaging guidance7989$71
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more2425$64
27096Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance1920$62

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
GabapentinGabapentin44515,733$4,068
PregabalinPregabalin992,940$1,816
Duloxetine HclDuloxetine Hcl1335,790$1,354
BaclofenBaclofen762,719$1,293
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen791,864$1,106

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.1$23Boston Scientific Corporation
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Ajitpal Grewal, M.D.?

Tedicare shows public-source Medicare data for Ajitpal Grewal, M.D. (NPI 1891105276), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ajitpal Grewal, M.D. have ACO affiliation data?

Ajitpal Grewal, M.D. is shown with ACO affiliation data for WellSpan Population Health Services (MSSP, ACO ID A2500).

What billing organization is linked to Ajitpal Grewal, M.D.?

Ajitpal Grewal, M.D. is linked to WELLSPAN MEDICAL GROUP (billing NPI 1518475029) in the available physician profile data.

Does Ajitpal Grewal, M.D. have Open Payments data?

Ajitpal Grewal, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.